Antituberculosis (anti-TB) drugs possess a variety of adverse effects, of which hepatotoxicity is the most common adverse effect as most of the anti-TB drugs are metabolized through the liver. Globally, the incidence of antituberculosis drug-induced hepatotoxicity (ATDH) ranges from 2% to 28% based on the definition of drug-induced liver injury, population of the study, and regimen of the treatment used. As documented in different studies, alcohol intake; elderly age; chronic liver disease; infections with hepatitis B virus (HBV), HCV, and HIV; advancement of TB; Asian ethnicity; female gender; concomitant use of enzyme-inducers; and poor nutritional status, were the possible risk factors for ATDH. Hepatic transaminase elevation without clinical presentation is a common and benign episode following anti-TB treatment, but symptomatic hepatotoxicity can be fatal without any intervention. Hepatotoxicity caused by antituberculous treatment (ATT) due to the combined use of drugs and long therapy period has been a major concern for clinical treatment. The rate of the liver injury due to ATT in developed and developing countries has been reported to be 4% and 39%, respectively. Hence, there is an urgent need to review the risk factors and predictors of hepatotoxicity identified in various studies so as to plan reliable clinical interventions for disease prevention or timely identification and to develop safer drug regimens.